Veru Inc.

Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and oncology. Its drug development program consists of two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass. Sabizabulin, an oral novel microtubule targeting agent that targets downstream components of the KRAS signaling pathway, has demonstrated the potential to become the next treatment for KRAS-driven metastatic pancreatic cancer resistant to the recent FDA approved daraxonrasib.

Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and oncology. The Company's drug development program consists of two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass to improve body composition and physical function. Sabizabulin, an oral novel microtubule targeting agent that targets downstream components of the KRAS signaling pathway, has demonstrated the potential to become the next treatment for KRAS-driven metastatic pancreatic cancer resistant to the recent FDA approved daraxonrasib. The Company plans to pursue a Phase 2b clinical study to evaluate the efficacy and safety of sabizabulin in patients for the treatment of metastatic pancreatic cancer after daraxonrasib failure, and will first seek regulatory clarity from the FDA through a preIND meeting in calendar Q4 2026.

Dedicated to developing and commercializing treatments for cardiometabolic and oncology.

• enobosarm

  An oral selective androgen receptor modulator (SARM) being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass.

• sabizabulin

  An oral novel microtubule targeting agent that targets downstream components of the KRAS signaling pathway, with potential to become the next treatment for KRAS-driven metastatic pancreatic cancer resistant to daraxonrasib.

1. 1Veru Inc. | A Biopharmaceutical Companyverupharma.com
2. 2About Veru | Veru Inc.verupharma.com